

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
------------------	----------------

NATURE OF CONVEYANCE:	ASSIGNMENT
-----------------------	------------

CONVEYING PARTY DATA

Name	Execution Date
Xantech Pharmaceuticals, Inc.	03/05/2007

RECEIVING PARTY DATA

Name:	Provectus Pharmatech, Inc.
Street Address:	7237 Oak Ridge Highway
City:	Knoxville
State/Country:	TENNESSEE
Postal Code:	37931

PROPERTY NUMBERS Total: 10

Property Type	Number
Application Number:	11124654
Application Number:	11429742
Application Number:	10999313
Application Number:	11187122
Application Number:	11522145
Application Number:	11542533
Application Number:	10331735
Application Number:	10925193
Application Number:	11049797
Application Number:	11050512

CORRESPONDENCE DATA

Fax Number: (312)236-8176  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
 Phone: 3122368500  
 Email: docket@cookalex.com

CH \$400.00 11124654

Correspondent Name: Mark J. Murphy  
Address Line 1: 200 West Adams Street  
Address Line 2: Suite 2850  
Address Line 4: Chicago, ILLINOIS 60606

ATTORNEY DOCKET NUMBER:	0546 - 10 FILES
-------------------------	-----------------

NAME OF SUBMITTER:	Mark J. Murphy
--------------------	----------------

Total Attachments: 4  
source=XantechtoProvectusPharma10files#page1.tif  
source=XantechtoProvectusPharma10files#page2.tif  
source=XantechtoProvectusPharma10files#page3.tif  
source=XantechtoProvectusPharma10files#page4.tif

## PATENT AND TRADEMARK ASSIGNMENT

This Patent Assignment ("Assignment") dated as of this 5th day of March, 2007 is entered into by and between Xantech Pharmaceuticals, Inc., a Tennessee corporation ("Assignor"), having an address at 7327 Oak Ridge Highway, Knoxville, Tennessee 37931 and Provectus Pharmatech, Inc., a Tennessee corporation ("Assignee"), having an address at 7237 Oak Ridge Highway, Suite A, Knoxville, Tennessee 37931.

WHEREAS, Assignor is the owner of \_\_\_\_\_ which certain patents have issued and certain patent applications are pending, as set forth in the attached Exhibit A (the "Patents"); and

WHEREAS, Assignee desires to \_\_\_\_\_.

NOW, THEREFORE, for consideration previously provided and hereby acknowledged, Assignor hereby:

1. Assigns, transfers, conveys and to Assignee the entire right, title and interest together with the benefits and privileges in and said to Patents (the patents and patent applications listed on Exhibit A attached hereto) or similar forms of protection in the United States of America and all other countries in the world, along with the related technical knowledge and know-how in and to the Patents, including all divisionals, continuations, continuation-in-parts, substitute applications, and international convention applications based in whole or part upon said inventions; and in and to any patents, certificates, utility models, reissues, extensions, additions or confirmations thereof which may be granted upon said inventions; and
2. Assignor agrees to execute, at the request of the Assignee, (i) all documents in connection with any application for United States letters patent or foreign letters patent for the Patents, (ii) any divisional, continuation or substitute application for the invention or improvements, and any oath, declaration or affidavit relating thereto, (iii) any application for the reissue or extension of any letters patent that may be granted upon the application, and (iv) all documents necessary to effectuate the assignments of the Trademarks. Assignor agrees to perform, upon request, any affirmative acts to obtain said letters patent of the United States or foreign letters patent and to vest in the Assignee all rights therein, so that the letters patent will be held and enjoyed by the Assignee, to the full end of the term for which said letters patent may be granted as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment had not been made. In the event that any application or letters patent that Assignor now assigns becomes involved in interference, Assignor agrees to cooperate with Assignee to prepare and execute the preliminary statement and giving and producing evidence in support thereof.


*Signature page follows.*

IN WITNESS WHEREOF, Assignor has executed this Assignment as of the date first above written.

Xantech Pharmaceuticals, Inc.

By:   
Dr. Craig Dees  
Chief Executive Officer

Provectus Pharmatech, Inc.

By:   
Dr. Craig Dees  
Chief Executive Officer

## EXHIBIT A

<u>TITLE</u>	<u>Application Serial No.</u>	<u>Application Filing Date</u>	<u>Patent No.</u>	<u>Issue Date</u>
High Energy Phototherapeutic Agents	11/124,654	5-9-2005		
Topical Medicaments And Methods For Photodynamic Treatment Of Disease	11/429,742	5-8-2006		
Intracorporeal Medicaments For Photodynamic Treatment of Disease	10/999,313	11-30-2004		
Intracorporeal Medicaments For Photodynamic Treatment of Disease	11/187,122	7-22-2005		
Intracorporeal Medicaments For Photodynamic Treatment of Disease	11/522,145	9-15-2006		
Intracorporeal Medicaments For High Energy Phototherapeutic Treatment of Disease	11/542,533	10/2/2006		
Medicaments For Chemotherapeutic Treatment of Disease	10/331,735	12-30-2002		

**EXHIBIT A (Cont'd)**

<u>TITLE</u>	<u>Application Serial No.</u>	<u>Application Filing Date</u>	<u>Patent No.</u>	<u>Issue Date</u>
Ultrasound Contrast Using Halogenated Xanthenes	10/925,193	8-24-2004		
Diagnostic Agents For Positron Emission Imaging Using Radiolabeled Halogenated Xanthenes	11/049,797	2-3-2005		
Methods For Positron Emission Imaging With Radiolabeled Halogenated Xanthenes Diagnostic Agents	11/050,512	2-3-2005		

<u>TITLE</u>	<u>Application Serial No.</u>	<u>Application Filing Date</u>	<u>Patent No.</u>	<u>Issue Date</u>
--------------	-----------------------------------	------------------------------------	-------------------	-------------------